These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 28551325)
1. Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Nowak K; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K Eur J Surg Oncol; 2017 Aug; 43(8):1550-1558. PubMed ID: 28551325 [TBL] [Abstract][Full Text] [Related]
2. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K Eur J Cancer; 2013 Oct; 49(15):3149-58. PubMed ID: 23800671 [TBL] [Abstract][Full Text] [Related]
3. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K; Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671 [TBL] [Abstract][Full Text] [Related]
4. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis. Zhang CD; Zeng YJ; Li HW; Zhao ZM; Zhang JK; Dai DQ Cancer Invest; 2013 Jul; 31(6):421-31. PubMed ID: 23758189 [TBL] [Abstract][Full Text] [Related]
6. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280 [TBL] [Abstract][Full Text] [Related]
7. The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis. Parry K; van Rossum PS; Haj Mohammad N; Ruurda JP; van Hillegersberg R Eur J Surg Oncol; 2017 Jan; 43(1):226-233. PubMed ID: 27424786 [TBL] [Abstract][Full Text] [Related]
8. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis. Ge L; Wang HJ; Yin D; Lei C; Zhu JF; Cai XH; Zhang GQ World J Gastroenterol; 2012 Dec; 18(48):7384-93. PubMed ID: 23326149 [TBL] [Abstract][Full Text] [Related]
10. Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone. Achiam MP; Jensen LB; Larsson H; Jensen LS; Larsen AC; Holm J; Svendsen LB Scand J Surg; 2016 Mar; 105(1):22-8. PubMed ID: 25794689 [TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Urschel JD; Vasan H; Blewett CJ Am J Surg; 2002 Mar; 183(3):274-9. PubMed ID: 11943125 [TBL] [Abstract][Full Text] [Related]
12. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767 [TBL] [Abstract][Full Text] [Related]
13. Impact of postoperative chemotherapy in patients with locally advanced gastroesophageal adenocarcinoma treated with perioperative chemotherapy strategy. Luc G; Gersen-Cherdieu H; Degrandi O; Terrebonne E; Chiche L; Collet D Am J Surg; 2015 Jul; 210(1):15-23. PubMed ID: 25957032 [TBL] [Abstract][Full Text] [Related]
14. [Preoperative neoadjuvant chemotherapy in esophago-cardial adenocarcinoma?]. Geissler M Dtsch Med Wochenschr; 2006 Jun; 131(23):1344. PubMed ID: 16761207 [No Abstract] [Full Text] [Related]
15. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials. Fu T; Bu ZD; Li ZY; Zhang LH; Wu XJ; Wu AW; Shan F; Ji X; Dong QS; Ji JF BMC Cancer; 2015 Apr; 15():322. PubMed ID: 25928286 [TBL] [Abstract][Full Text] [Related]
16. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. Zahoor H; Luketich JD; Levy RM; Awais O; Winger DG; Gibson MK; Nason KS J Thorac Cardiovasc Surg; 2015 Feb; 149(2):538-47. PubMed ID: 25454907 [TBL] [Abstract][Full Text] [Related]
17. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271 [TBL] [Abstract][Full Text] [Related]
18. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917 [TBL] [Abstract][Full Text] [Related]
19. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis. Mokdad AA; Yopp AC; Polanco PM; Mansour JC; Reznik SI; Heitjan DF; Choti MA; Minter RR; Wang SC; Porembka MR JAMA Oncol; 2018 Jan; 4(1):31-38. PubMed ID: 28975352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]